Literature DB >> 15948786

Random measurement error in visual acuity measurement in clinical settings.

Jaakko Leinonen1, Eero Laakkonen, Leila Laatikainen.   

Abstract

PURPOSE: To estimate the random measurement error in visual acuity (VA) determination in the clinical environment in cataractous, pseudophakic and healthy eyes.
METHODS: The VAs of patients referred for cataract surgery or consultation by ophthalmic professionals were re-examined and the VA results for distance using projector acuity charts were compared. Refractive errors were also remeasured. A total of 99 eyes (41 cataractous, 36 pseudophakic and 22 healthy eyes) were examined. The healthy comparison group consisted of hospital staff. Only one eye of each person and eyes with Snellen VAs of 0.3-1.3 (logMAR 0.52 to - 0.11) were included. The mean time interval between the first and second examinations was 45 days.
RESULTS: The estimated standard deviation of measurement error (SDME) of repeated VA measurements of all eyes was logMAR 0.06. Eyes with the lowest VA (0.3-0.45) had the largest variability (SDME logMAR 0.09), and eyes with VA > or = 0.7 had the smallest (SDME logMAR 0.04). The variability may be partly explained by the line size progression in lower VAs, partly by the difference in the remeasurement of the refractive error. The difference in the average VA between examinations 1 and 2 (logMAR 0.15 versus 0.12) was considered to be of some interest because it indicates that some learning effect is possible.
CONCLUSION: Visual acuity results in clinical settings have a certain degree of inherent variability. In this series variability ranged from SDME logMAR 0.04 (eyes with good vision) to logMAR 0.09 (in the lower vision group) in the Snellen VA range of 0.3-1.3. Changes should be judged with caution, especially in cases of decreased VA.

Entities:  

Mesh:

Year:  2005        PMID: 15948786     DOI: 10.1111/j.1600-0420.2005.00469.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  5 in total

1.  Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome.

Authors:  Heinrich Gerding; Vlassios Loukopoulos; Juliane Riese; Lars Hefner; Melanie Timmermann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-09       Impact factor: 3.117

2.  Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis).

Authors:  Peter K Kaiser
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

3.  Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts.

Authors:  Iryna A Falkenstein; Denine E Cochran; Stanley P Azen; Laurie Dustin; Ajay M Tammewar; Igor Kozak; William R Freeman
Journal:  Ophthalmology       Date:  2007-08-13       Impact factor: 12.079

Review 4.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

5.  HAS SNELLEN CHART LOST THE BATTLE TO ETDRS IN CATARACT SURGERY VISUAL ACUITY EVALUATION?

Authors:  Sanja Petrović Pajić; Tiana Petrović; Milenko Stojković; Slađana Anđelić
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.780

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.